The Lancet Oncology· Sagar Lonial, Meletios A Dimopoulos, Maria Gavriatopoulou, Kihyun Kim, Chang-Ki Min, Albert Oriol, Catarina Campos Costa Moreira, Hang Quach, Lugui Qiu, Zhongjun Xia, Fredrik Schjesvold, Ignacio Casas-Avilés, Yan Xu, Vania Hungria, Güldane C Seval, Baijun Fang, Charalampia Kyriakou, Henry Miles Prince, Junling Zhuang, Hsin-Chen Lin, María-Victoria Mateos, Ivan Špička, Angelo Maiolino, Filiz Vural, Supratik Basu, Dominik Dytfeld, Chengcheng Fu, Phoebe Joy Ho, Nisha Joseph, Michael Low, Ludek Pour, Saulius Girnius, Jesús G Berdeja, Paula Rodríguez Otero, Yiming Cheng, Michael Amatangelo, Sarah Hersey, Christian Kazanecki, Marija Bosilkovska Weisskopf, Margee J Kyada, Patricia C Abad, Shuyu Chu, Juliane Morando, Paulo Maciag, Paul G Richardson, Niels WCJ van de Donk, EXCALIBER-RRMM Investigators·· 7 天前精选评分69
Iberdomide 联合达雷妥尤单抗和地塞米松 vs 达雷妥尤单抗、硼替佐米和地塞米松治疗复发难治多发性骨髓瘤的 3 期试验结果
[Articles] Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial
导读
Iberdomide 联合达雷妥尤单抗和地塞米松相比达雷妥尤单抗、硼替佐米和地塞米松显著提高了 MRD 阴性完全缓解率。最常见 3-4 级不良事件为血液学事件和感染，多数可通过标准支持治疗管理。这些结果支持该方案作为复发难治多发性骨髓瘤的有效治疗选择，且有望在不同诊疗场景中实施。
推荐理由
试验直接比较了含 iberdomide 的新方案与标准方案在 MRD 阴性完全缓解率上的差异，为复发难治骨髓瘤提供了潜在门诊适用方案。
来源：The Lancet Oncology · thelancet.com